• Substance P Workflows for NK-1 Signaling Research

  2026-08-30

  Build more reproducible pain transmission research and neuroimmune assays with an aqueous, high-purity Substance P peptide. This guide combines receptor-focused dosing, matrix-aware fluorescence quality control, and practical troubleshooting for cell-based and analytical workflows.

• ERK5 and Vitamin D–Driven AML Differentiation

  2026-08-29

  Wang and colleagues identify the MEK5–ERK5 branch of MAPK signaling as a major regulator of 1α,25-(OH)₂ vitamin D₃-induced terminal differentiation in HL60 and U937 myeloid leukemia cells. The study shows that ERK5 inhibition produces a distinct differentiation and cell-cycle phenotype from ERK1/2 inhibition, providing a mechanistic basis for pathway-selective combination strategies.

• Vidarabine monohydrate: Assay Reliability Guide

  2026-08-29

  This scenario-based guide explains how Vidarabine monohydrate (SKU C6377) can be handled and interpreted in antiviral, cell viability, proliferation, and cytotoxicity workflows. It focuses on documented purity, DMSO solubility, storage, controls, and vendor-selection criteria rather than unsupported performance claims.

• ASCH Proteins and N4-Acetylcytidine Processing

  2026-08-28

  Meng et al. resolve how the Escherichia coli ASCH-domain protein EcYqfB hydrolyzes free N4-acetylcytidine to cytidine while showing that it does not remove ac4C from RNA. Structural comparisons with mouse EOLA1 and the human TRIP4-ASCH domain clarify how related proteins can differ in substrate recognition, with practical implications for RNA epigenetics research and nucleotide-processing assays.

• DOM Hallucinogen Responses: 5-HT2C/1A Modulation

  2026-08-28

  This 2024 Psychopharmacology study separates the receptor mechanisms underlying DOM-induced head twitch response and locomotor activity in mice. Its pharmacological design shows that 5-HT2A signaling is essential for head twitching, whereas 5-HT2C, 5-HT1A, and Gi/o-linked pathways help shape the distinct inverted U-shaped behavioral responses.

• Cy5 Goat Anti-Rabbit IgG (H+L) Antibody: Lab Guide

  2026-08-27

  A scenario-based guide to using Cy5 Goat Anti-Rabbit IgG (H+L) Antibody, SKU K1212, for reproducible endpoint immunofluorescence in viability, proliferation, cytotoxicity, and antiviral signaling studies. It covers compatibility, controls, storage, optimization, quantitative interpretation, and practical vendor-selection criteria.

• Sulfachloropyridazine Workflows for Folate Research

  2026-08-27

  Sulfachloropyridazine connects DHPS-focused enzyme studies with antimicrobial susceptibility testing, microbiome profiling, and carefully controlled infection-model research. This guide translates its insoluble-in-water formulation and strain-dependent activity into practical preparation, assay, interpretation, and troubleshooting workflows.

• HLTP1 Targets JNK in Hepatic Ischemia-Reperfusion Injury

  2026-08-26

  A 2026 World Journal of Gastroenterology study used peptidomics of human liver-transplant samples to identify human liver transplantation peptide 1 (HLTP1), a candidate hepatoprotective peptide. In mouse and AML12-cell models, HLTP1 reduced hepatic ischemia-reperfusion injury and apoptosis, with rescue experiments implicating suppression of Jun N-terminal kinase phosphorylation.

• BMS-345541 Workflow for NF-κB Studies

  2026-08-26

  BMS-345541 is an IKK-1/IKK-2 inhibitor for connecting NF-κB activity with cytokine release, angiogenic behavior, and cancer-cell survival. This practical guide shows how to prepare the free base, build dose-responsive workflows, and distinguish pathway-specific effects from solvent, timing, or viability artifacts.

• Relative Viability vs Cell Killing in Cancer Drug Tests

  2026-08-25

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different combinations of proliferative arrest and cell death. The work provides a practical framework for interpreting drug-response experiments by considering response magnitude, biological endpoint, and timing together.

• 5-Aminolevulinic acid HCl in Heme Assays

  2026-08-25

  5-Aminolevulinic acid HCl provides a practical downstream entry point for testing heme-pathway control in bacterial infection models, macrophage assays, and porphyrin-focused cancer research. Its water solubility and pathway position also support controlled comparisons between microbial virulence phenotypes and fluorescence-based mammalian applications.

• (S)-(+)-Ibuprofen: From COX to Ecosystems

  2026-08-24

  Explore how (S)-(+)-Ibuprofen functions as a COX inhibitor across molecular, cellular, and environmental research. This evidence-led guide connects stereochemistry, prostaglandin suppression, assay design, and ecotoxicological interpretation.

• Griseofulvin: From Antifungal Action to Assay Design

  2026-08-23

  Griseofulvin is a microtubule associated inhibitor with value beyond conventional antifungal drug research. This article shows how compound handling, multiparameter flow cytometry, and mechanistic controls can improve interpretation of fungal cell mitosis inhibition and aneugenicity studies.

• Baicalin methyl ester for Intestinal Barrier Assays

  2026-08-22

  Baicalin methyl ester provides a mechanistically focused tool for modeling LPS-induced intestinal barrier damage, linking inflammatory signaling with tight-junction and epithelial-readout assays. This guide translates product specifications into practical cell, dosing, solubility, troubleshooting, and translational workflows.

• Flavopiridol: Separating CDK and ER Stress Effects

  2026-08-21

  Flavopiridol (L868275) is examined as a cell cycle arrest agent through a new assay framework that separates direct CDK inhibition from endoplasmic reticulum stress. The article translates intestinal stem cell findings into practical decisions for cancer research, pathway validation, and mechanistic interpretation.

448 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page